Monitor for announcement of a new European licensing partner for D-PLEX₁₀₀, which would validate the asset's commercial potential outside North America. The FDA NDA and EMA submissions are the next key catalysts; any regulatory updates will significantly impact the stock.
Price Chart
Executive Summary
PolyPid and ADVANZ PHARMA mutually terminated their 2022 exclusive European license agreement for D-PLEX₁₀₀, reverting European commercialization rights to PolyPid. The termination comes after key milestones including positive Phase 3 SHIELD II data, NDA submission to the FDA, and a recently announced North American partnership with Azurity Pharmaceuticals. PolyPid now seeks a new European partner for D-PLEX₁₀₀, which has a validated Phase 3 profile and pending regulatory submissions.
Key Facts
- PolyPid and ADVANZ PHARMA mutually terminated the 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe.
- European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.
- PolyPid completed the Phase 3 SHIELD II trial, NDA submission to the FDA, and EMA submission since the original 2022 agreement.
- PolyPid recently announced a North American commercialization partnership with Azurity Pharmaceuticals.
- PolyPid is evaluating potential European commercialization opportunities with multinational pharmaceutical companies.
Financial Impact
No financial terms of the termination or any new agreement were disclosed. The loss of a pre-arranged European partner creates near-term uncertainty, but the asset's validated Phase 3 profile and pending regulatory submissions may attract a new partner.
Risk Factors
- No new European partner identified yet; potential delay in European commercialization.
- Regulatory outcomes (FDA NDA, EMA) remain binary and could affect partner interest.
- PolyPid may need to invest in European commercial infrastructure if no partner is found.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372922 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 13w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers